CGC Quote, Financials, Valuation and Earnings

Edesa Biotech, Inc. has a net margin of -2.46% compared to Canopy Growth Corp.'s net margin of --. Canopy Growth Corp.'s return on equity of -67.7% beat Edesa Biotech, Inc.'s return on equity of -80.46%.

Canopy Growth Corp. has a consensus price target of $3.82, signalling upside risk potential of 231.09%. On the other hand Edesa Biotech, Inc. has an analysts' consensus of $10.33 which suggests that it could grow by 538.5%. Given that Edesa Biotech, Inc. has higher upside potential than Canopy Growth Corp., analysts believe Edesa Biotech, Inc. is more attractive than Canopy Growth Corp..

Canopy Growth Corp. has a beta of 0.403, which suggesting that the stock is 59.734% less volatile than S&P 500. In comparison Edesa Biotech, Inc. has a beta of 0.078, suggesting its less volatile than the S&P 500 by 92.204%.

Canopy Growth Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Canopy Growth Corp. pays -- of its earnings as a dividend. Edesa Biotech, Inc. pays out -- of its earnings as a dividend.

Canopy Growth Corp. quarterly revenues are $48.4M, which are larger than Edesa Biotech, Inc. quarterly revenues of --. Canopy Growth Corp.'s net income of -$1.2M is higher than Edesa Biotech, Inc.'s net income of -$1.7M. Notably, Canopy Growth Corp.'s price-to-earnings ratio is -- while Edesa Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Canopy Growth Corp. is 1.06x versus 31.22x for Edesa Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Lexaria Bioscience Corp. has a net margin of -2.46% compared to Canopy Growth Corp.'s net margin of -2178.51%. Canopy Growth Corp.'s return on equity of -67.7% beat Lexaria Bioscience Corp.'s return on equity of -147.19%.

Canopy Growth Corp. has a consensus price target of $3.82, signalling upside risk potential of 231.09%. On the other hand Lexaria Bioscience Corp. has an analysts' consensus of $6.00 which suggests that it could grow by 380.48%. Given that Lexaria Bioscience Corp. has higher upside potential than Canopy Growth Corp., analysts believe Lexaria Bioscience Corp. is more attractive than Canopy Growth Corp..

Canopy Growth Corp. has a beta of 0.403, which suggesting that the stock is 59.734% less volatile than S&P 500. In comparison Lexaria Bioscience Corp. has a beta of 0.628, suggesting its less volatile than the S&P 500 by 37.221%.

Canopy Growth Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Canopy Growth Corp. pays -- of its earnings as a dividend. Lexaria Bioscience Corp. pays out -- of its earnings as a dividend.

Canopy Growth Corp. quarterly revenues are $48.4M, which are larger than Lexaria Bioscience Corp. quarterly revenues of $174K. Canopy Growth Corp.'s net income of -$1.2M is higher than Lexaria Bioscience Corp.'s net income of -$2.7M. Notably, Canopy Growth Corp.'s price-to-earnings ratio is -- while Lexaria Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Canopy Growth Corp. is 1.06x versus 28.32x for Lexaria Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Oncolytics Biotech, Inc. has a net margin of -2.46% compared to Canopy Growth Corp.'s net margin of --. Canopy Growth Corp.'s return on equity of -67.7% beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.

Canopy Growth Corp. has a consensus price target of $3.82, signalling upside risk potential of 231.09%. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.49 which suggests that it could grow by 505.14%. Given that Oncolytics Biotech, Inc. has higher upside potential than Canopy Growth Corp., analysts believe Oncolytics Biotech, Inc. is more attractive than Canopy Growth Corp..

Canopy Growth Corp. has a beta of 0.403, which suggesting that the stock is 59.734% less volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.880, suggesting its less volatile than the S&P 500 by 11.965%.

Canopy Growth Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Canopy Growth Corp. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.

Canopy Growth Corp. quarterly revenues are $48.4M, which are larger than Oncolytics Biotech, Inc. quarterly revenues of --. Canopy Growth Corp.'s net income of -$1.2M is higher than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, Canopy Growth Corp.'s price-to-earnings ratio is -- while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Canopy Growth Corp. is 1.06x versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Tilray Brands, Inc. has a net margin of -2.46% compared to Canopy Growth Corp.'s net margin of 0.72%. Canopy Growth Corp.'s return on equity of -67.7% beat Tilray Brands, Inc.'s return on equity of -84.8%.

Canopy Growth Corp. has a consensus price target of $3.82, signalling upside risk potential of 231.09%. On the other hand Tilray Brands, Inc. has an analysts' consensus of $17.83 which suggests that it could grow by 152.6%. Given that Canopy Growth Corp. has higher upside potential than Tilray Brands, Inc., analysts believe Canopy Growth Corp. is more attractive than Tilray Brands, Inc..

Canopy Growth Corp. has a beta of 0.403, which suggesting that the stock is 59.734% less volatile than S&P 500. In comparison Tilray Brands, Inc. has a beta of 1.758, suggesting its more volatile than the S&P 500 by 75.794%.

Canopy Growth Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tilray Brands, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Canopy Growth Corp. pays -- of its earnings as a dividend. Tilray Brands, Inc. pays out -- of its earnings as a dividend.

Canopy Growth Corp. quarterly revenues are $48.4M, which are smaller than Tilray Brands, Inc. quarterly revenues of $209.5M. Canopy Growth Corp.'s net income of -$1.2M is lower than Tilray Brands, Inc.'s net income of $1.5M. Notably, Canopy Growth Corp.'s price-to-earnings ratio is -- while Tilray Brands, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Canopy Growth Corp. is 1.06x versus 8.10x for Tilray Brands, Inc.. Usually stocks with elevated PS ratios are considered overvalued.